Sofinnova Investments’s Altamira Therapeutics Ltd CYTO Stock Holding History

Sofinnova Investments’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-18	Closed	–	–	70
2018 Q3	$0	Hold	18	–	–	﹤0.01%	65
2018 Q2	$0	Sell	18 -80	-82%	-$844K	﹤0.01%	70
2018 Q1	$1.25M	Buy	+98	New	+$2.62M	0.22%	18

Other funds holding CYTO

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sofinnova Investments's CYTO Position: Q4 2018 in Review

Sofinnova Investments sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2018, closing a stake of 18 shares.

Sofinnova Investments first reported a position in CYTO in Q1 2018 and held it in 3 quarters. The position peaked at $1.25M in Q1 2018. 8 funds tracked by Wall St. Rank hold CYTO as of Q4 2018.

Sofinnova Investments reported no remaining Altamira Therapeutics Ltd position as of Q4 2018 after selling out during the quarter.
Sofinnova Investments sold 18 Altamira Therapeutics Ltd shares in Q4 2018.
Sofinnova Investments first reported a position in Altamira Therapeutics Ltd in Q1 2018 and held it in 3 quarters.
Sofinnova Investments's Altamira Therapeutics Ltd position peaked at $1.25M in Q1 2018.
8 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2018.

Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.